Vera Therapeutics VERA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -71.3%-20.6pp | -50.7%+22.5pp | -73.2%-18.4pp | -54.8%-15.3pp | -39.5%+5.3pp | |
| Return on assets | -59.9%-16.8pp | -43.1%+13.8pp | -56.9%-12.1pp | -44.7%-10.7pp | -34.1%+2.5pp | |
| Return on invested capital | -77.1%-4.3pp | -72.8%+0.7pp | -73.5%-18.1pp | -55.4%-11.1pp | -44.3%+7.2pp | |
| Liquidity | ||||||
| Current ratio | 13.6×0.0× | 13.6×+1.4× | 12.2×-4.8× | 17×-10.7× | 27.7×+2.0× | |
| Quick ratio | 13.6×0.0× | 13.6×+1.4× | 12.2×-4.8× | 17×-10.7× | 27.7×+2.0× | |
| Cash ratio | 2.5×-4.1× | 6.6×+5.3× | 1.4×-0.1× | 1.5×-1.1× | 2.5×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.1×-0.1× | 0.2×0.0× | 0.2×+0.1× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -50.7×-8.8× | -41.9×-5.9× | -36×-4.5× | -31.6×-5.9× | -25.7×-3.8× | |
| Per Share | ||||||
| Book value per share | $6.99-25.7% | $9.41+50.6% | $6.25-14.9% | $7.34-12.6% | $8.40-19.5% | |
| Valuation | ||||||
| Market capitalization | $2.87B-20.1% | $3.59B+93.8% | $1.85B+28.8% | $1.44B-6.0% | $1.53B-42.8% | |
| Enterprise value | $2.83B-14.7% | $3.32B+77.0% | $1.87B+27.6% | $1.47B-4.1% | $1.53B-42.0% | |
| Price / book | 5.7×-0.2× | 5.9×+1.3× | 4.6×+1.6× | 3.1×+0.2× | 2.9×-1.8× | |
| Free cash flow yield | -10.2%-3.5pp | -6.7%+4.7pp | -11.4%+1.6pp | -13%-2.7pp | -10.2%-5.1pp | |
| Earnings yield | -12.9%-4.5pp | -8.3%+5.2pp | -13.6%+1.6pp | -15.2%-3.7pp | -11.5%-5.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vera Therapeutics's ratios come from?
- Every ratio is computed from Vera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.